Prospective Evaluation of the Carbon Footprint and Clinical Utility of IBUS Compared to Colonoscopy and Enterography in UC and CD
Recruiting · NCT07431983 · Observational (researchers observe without assigning treatment) · Lead sponsor: Asian Institute of Gastroenterology, India
View the official record on ClinicalTrials.gov →What this trial is about
Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, sterilisation, and transportation. IBUS, a non-invasive, real-time diagnostic modality, is increasingly validated for disease activity assessment in both UC and CD.
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Eligibility criteria (as published)
All consecutive patients undergoing endoscopy procedures with consent for procedures, during the study period will be included
Where it is running
4 locations listed.
- AIG Hospitals - Hyderabad, Telangana, India
- AIG Hospitals - Hyderabad, Telangana, India
- AIG Hospitals - Hyderabad, Telangana, India
- AIG Hospitals - Hyderabad, Telangana, India